ROS clearance, mitochondrial protection, and CaMKII/CREB pathway activation are promising treatments for glaucoma.[36, 37, 38, 39] In this study, we developed hypoxia and ROS dual response nano drugs (HOLN‐NPs), which can release Nico and OA under hypoxic environments and ROS conditions. This evidence concerns the gene CREB1 and glaucoma.